Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27403321)

Published in BMJ Open Respir Res on June 17, 2016

Authors

Emanuel Citgez1, Job van der Palen2, Kirsten Koehorst-Ter Huurne3, Kris Movig4, Paul van der Valk3, Marjolein Brusse-Keizer5

Author Affiliations

1: Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, The Netherlands; Department of Research Methodology, Measurement, and Data analysis, University of Twente, Enschede, The Netherlands.
2: Medical School Twente, Medisch Spectrum Twente, Enschede, The Netherlands; Department of Research Methodology, Measurement, and Data analysis, University of Twente, Enschede, The Netherlands.
3: Department of Pulmonary Medicine , Medisch Spectrum Twente , Enschede , The Netherlands.
4: Department of Clinical Pharmacy , Medisch Spectrum Twente , Enschede , The Netherlands.
5: Medical School Twente, Medisch Spectrum Twente , Enschede , The Netherlands.

Articles cited by this

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med (2004) 18.60

Immortal time bias in pharmaco-epidemiology. Am J Epidemiol (2007) 6.98

Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet (2009) 5.51

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest (2007) 4.96

Chronic obstructive pulmonary disease. Lancet (2012) 4.43

Evaluation of clinical methods for rating dyspnea. Chest (1988) 4.12

Estimating medication persistency using administrative claims data. Am J Manag Care (2005) 3.95

Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51

Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68

Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med (2007) 2.65

Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med (2013) 2.29

New insights into the immunology of chronic obstructive pulmonary disease. Lancet (2011) 2.23

Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol (2006) 1.91

Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) (2009) 1.69

Statin use is associated with reduced mortality in COPD. Eur Respir J (2006) 1.66

Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J (2012) 1.58

Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med (2008) 1.54

Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J (2013) 1.45

Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract (2008) 1.20

The use of statins and lung function in current and former smokers. Chest (2007) 1.18

Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev (2009) 1.10

Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther (2012) 1.04

Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med (2012) 1.03

Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.03

Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open (2012) 1.03

Associations between statins and COPD: a systematic review. BMC Pulm Med (2009) 0.99

Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax (2014) 0.93

Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies. Respir Res (2014) 0.90

Differences in Adherence to Common Inhaled Medications in COPD. COPD (2015) 0.82

Stable state MR-proadrenomedullin level is a strong predictor for mortality in COPD patients. Chest (2013) 0.79

Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review. Pulm Pharmacol Ther (2014) 0.79

[Prevalence of cold in Vlagtwedde and Vlaardingen (computer diagnosis versus doctors' diagnosis)]. Ned Tijdschr Geneeskd (1975) 0.78